Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Other Non-Current Assets: 2023-2024

Historic Other Non-Current Assets for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $12.9 million.

  • Zenas BioPharma's Other Non-Current Assets rose 53.02% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 53.02%. This contributed to the annual value of $12.9 million for FY2024, which is 76.69% up from last year.
  • According to the latest figures from FY2024, Zenas BioPharma's Other Non-Current Assets is $12.9 million, which was up 76.69% from $7.3 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Other Non-Current Assets registered a high of $12.9 million during FY2024, and its lowest value of $7.3 million during FY2023.
  • Moreover, its 2-year median value for Other Non-Current Assets was $10.1 million (2023), whereas its average is $10.1 million.
  • Data for Zenas BioPharma's Other Non-Current Assets shows a peak YoY spiked of 76.69% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Other Non-Current Assets (Yearly) stood at $7.3 million in 2023, then spiked by 76.69% to $12.9 million in 2024.